Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1254741 | 0.91 | TLR7 (0.51) | TLR7HASPINALDH1A1HPGDKDM4E | |
| SCHEMBL14900238 | 0.89 | HASPIN (0.43) | TLR7HASPINALDH1A1HPGDKDM4E | |
| SCHEMBL7564825 | 0.84 | TLR7 (0.47) | TLR7HASPINALDH1A1HPGDKDM4E | |
| SCHEMBL1829942 | 0.81 | HASPIN (0.44) | TLR7HASPINALDH1A1HPGDKDM4E | |
| SCHEMBL14889085 | 0.81 | TLR7 (0.45) | TLR7HASPINALDH1A1MAPK1MAPT | |
| SCHEMBL22130771 | 0.81 | TLR7 (0.45) | TLR7HASPINMAPK1MAPTLMNA | |
| SCHEMBL20997798 | 0.80 | TLR7 (0.54) | TLR7HASPINMAPTGAATDP1 | |
| SCHEMBL16142515 | 0.80 | TLR7 (0.44) | TLR7HASPINALDH1A1POLBMAPT | |
| SCHEMBL7480837 | 0.80 | TLR7 (0.43) | TLR7HASPINALDH1A1HPGDMAPK1 | |
| SCHEMBL8079399 | 0.79 | KMT2A (0.42) | HASPINALDH1A1MAPK1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011605-B2 | Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds | FLAMMA SPA (IT) | 2018-07-03 | — | — | US | disclosed |
| US-9469614-B2 | Synthesis of triazolopyrimidine compounds | LEK PHARMACEUTICALS D.D. (SI) | 2016-10-18 | — | — | US | disclosed |
| US-20140256747-A1 | Synthesis of Triazolopyrimidine Compounds | LEK PHARMACEUTICALS D.D. (SI) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256747-A1 | Synthesis of Triazolopyrimidine Compounds | DPYD, TYMS, TYMP | TLR7 4357/4885HASPIN 1887/4885ALDH1A1 1487/4885 |
| US-10011605-B2 | Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds | TBXA2R, THPO, P2RY4 | TLR7 3243/4885HASPIN 2053/4885ALDH1A1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.